CLOS
MRTX

Compagnie Lombard Odier SCmA’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-43,428
Closed -$7.44M – 705
2021
Q1 		$7.44M Buy
+43,428
New +$8.6M 0.16% 95

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Compagnie Lombard Odier SCmA's MRTX Position: Q2 2021 in Review

Compagnie Lombard Odier SCmA sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2021, closing a stake of 43,428 shares — an estimated $7.44M sold.

Compagnie Lombard Odier SCmA first reported a position in MRTX in Q1 2021 and held it in 1 quarter. The position peaked at $7.44M in Q1 2021. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

  • Compagnie Lombard Odier SCmA reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 43,428 Mirati Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $7.44M.
  • Compagnie Lombard Odier SCmA first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Compagnie Lombard Odier SCmA's Mirati Therapeutics, Inc. Common Stock position peaked at $7.44M in Q1 2021.
  • 245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2021, filed 15 Jul 2021.